<DOC>
	<DOCNO>NCT00160693</DOCNO>
	<brief_summary>The primary purpose study obtain long-term safety data CZP patient Rheumatoid Arthritis ( RA ) . Additional objective assess dose type Arthritis medication ( ) utilize patient , assess long-term impact CZP physical function . Treatment continue approval marketing application product .</brief_summary>
	<brief_title>Open Label Long-Term Safety Study Certolizumab Pegol ( CZP ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Participation CZP trial C87014 C87011 If female childbearing potential , agree participate study provide write informed consent , use adequate contraception since last menses , use adequate contraception study 12 week last dose study drug ( longer require local regulation ) , lactate , negative urine pregnancy test day receive first dose study drug Must provide write informed consent undergo study procedure History ( Hx ) chronic infection , serious lifethreatening infection ( include Herpes Zoster ) within 6 month prior , current symptom indicate infection Current recent Hx severe , progressive and/or uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological cerebral disease Any find indicative Tuberculosis end previous study Known HIV infection Persistently abnormal AST ( Aspartate Aminotransferase ) ALT ( Alanine Aminotransferase ) result ( &gt; 2 time upper limit normal ) Hemoglobin ( Hgb ) level &lt; 9 g/dL Hematocrit &lt; 30 % Total White Blood Cell ( WBC ) count &lt; 3.0 x 100/L ( &lt; 3000/mm^3 ) Platelet count &lt; 100 x 100 L ( 100,000/mm^3 ) Serum creatinine &gt; 1.5 time upper limit normal base patient age sex Receipt biological therapy RA 6 month prior study entry prior treatment ( tx ) Tumor Necrosis Factor ( TNF ) block agent ( exclude CDP870 ) Receipt vaccination ( live , attenuate kill ) 8 week prior Baseline Any condition Principal Investigator judge would make patient unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>America College Rheumatology</keyword>
	<keyword>Disease modify anti-rheumatic drug</keyword>
	<keyword>Certolizumab Pegol ( CDP870 )</keyword>
</DOC>